Search

everythinglearnresearchcommunity

for

Search:↓

The conversation humorously discusses various hair loss treatments and options, including Minoxidil, finasteride, RU58841, biotin, ketoconazole, saw palmetto, dutasteride, and nutrition. It also mentions hair extensions and hairstyling as methods to achieve desired hairstyles.

PP405 is being discussed as a potential hair loss treatment, possibly more effective than minoxidil. There are concerns about its effectiveness and product contamination, but some users report early signs of hair regrowth.

A group buy for hair loss treatments including Harmine 19a, TM5614, Abiraterone Acetate, and others. A compound, BMS-202, that can potentially reverse gray hair is also mentioned.

PP405 is the most promising future treatment for hair loss, aiming to reactivate dormant hair follicles. Clascoterone 5% is the most promising near-term drug, while current strategies include using finasteride or dutasteride to stabilize hair loss and minoxidil to stimulate growth.

KX-826/pyrilutamide is undergoing an additional one-year safety and efficacy trial in China after a six-month study. Some participants speculate on the reasons for the extended trial and discuss the potential of other treatments.

A user is considering adding PRP and mesotherapy to their hair loss treatment and is deciding between two options: Promoitalia, which contains Phosphatidic acid, Riboflavin, and Superoxide dismutase, and the more expensive Melsmon, a human placenta derivative. They seek advice on which option to choose based on effectiveness and scientific backing.

Breezula, a potential new hair loss treatment, may receive FDA approval soon, but it is expected to be a weaker alternative to finasteride and minoxidil. Concerns include its twice-daily application and possible side effects like HPA axis suppression.

A clinical trial for Verteporfin as a hair loss treatment, and the potential for greater progress in treatments for hair loss in the future. Common treatments such as Minoxidil, Finasteride and RU58841 were discussed.

The user shared minimal results from using JXL-069 for hair loss, noting a slight lengthening of vellus hairs and plans to switch to a prodrug variant due to limited effectiveness. They also mentioned using finasteride and minoxidil, which have plateaued in results.

Hair loss treatments Fin and Minoxidil failed for user. Suggested alternatives are 75mg oral spiro and RU58841, but concerns about low testosterone and self-esteem were raised.

Minoxidil increases hair count despite high prolactin being linked to hair loss. Blocking DHT is effective, but not always necessary; HMI-115 is a promising treatment for androgenetic alopecia.

Ordering pyrilutamide and minoxidilmax's quality. Seeking good source for purchase.

A user started using RU58841 for hair loss and experienced anxiety and physical discomfort. Other users suggested avoiding the treatment due to similar side effects and recommended alternative treatments like pyri.

The conversation is about hair loss and the use of specific treatments like minoxidil, finasteride, and RU58841.

Melatonin is being explored as a hair loss treatment, with one user mixing it into minoxidil but not seeing results. The conversation discusses experimenting with melatonin concentrations.

A user shared a vlog about their experience using 5mg of pyrilutamide daily for hair loss, including before and after pictures.

Verteporfin is being discussed for its potential to regrow hair and heal scars, possibly aiding hair transplants or replacing them. Some users are skeptical about its effectiveness, while others suggest combining it with microneedling for better results.

Hair loss treatments include finasteride, minoxidil, microneedling, dutasteride, CB-03-01, RU-58841, and experimental options like KY-19382 and stem cell therapy. Some treatments are considered ineffective or risky, such as ketoconazole, PRP, and low-level laser therapy.

User noticed receding temples, used minoxidil and microneedling with positive results. Added saw palmetto and eucapil, experienced shedding and thinner hairline, but no side effects.

GT-20029 is discussed as a potential hair loss treatment, with concerns about its safety and systemic absorption compared to finasteride. Users express skepticism about its effectiveness and safety, noting that it may not surpass existing treatments like finasteride and minoxidil.

A user is experiencing facial bloating from low-dose topical finasteride due to high estradiol levels and is seeking advice on using DIM to manage this issue, including dosage and brand recommendations.

The conversation humorously discusses various hair loss treatments and alternatives, including finasteride, minoxidil, and rosemary oil, with some users joking about wigs and unconventional items like roadkill. One user mentions using oral finasteride and minoxidil, topical rosemary oil, and microneedling.

The FDA policy change may speed up approval for hair loss drugs like PP405, VDPHL-01, and Breezula by potentially eliminating the need for a second confirmatory Phase 3 trial. Approval timelines could be as early as 2028 for some treatments if Phase 3 results are strong.

The conversation discusses the safety and effectiveness of a hair loss drug, GT20029, and the possibility of infrequent application, with users hoping for once-daily use and speculating on the drug's duration of effect on the scalp. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

This conversation discussed the potential for a hair loss treatment alternative to minoxidil, with many users debating the economic and health implications of such an option. Some suggested that finasteride could be used as an alternative, while others argued that this would ultimately not benefit pharmaceutical companies due to their reliance on planned obsolescence.

The conversation discusses the potential benefits of creating a hydrophobic version of finasteride to reduce systemic side effects while maintaining scalp health. It compares this idea to fluridil, which is designed to be hydrophobic and has less systemic absorption.

Epristeride is a selective 5 alpha reductase type 2 inhibitor that may reduce scalp DHT similarly to finasteride, with potentially fewer side effects. It is suggested that combining epristeride with finasteride or dutasteride could enhance hair loss treatment effectiveness.

The conversation is about whether stemoxydine can shorten the dormant phase after a hair transplant, known as the ugly duckling phase. There is skepticism about whether it actually works as claimed.

A new painless microneedle patch shows promise in reversing hair loss. The discussion focuses on potential new treatments beyond common options like Minoxidil, finasteride, and RU58841.

Latanoprost at 0.1% concentration is used to increase hair counts, often mixed with Minoxidil and Finasteride. Users report noticeable results in about 3 months.